Erythromelalgia (Investigational)
Highly investigational use for primary or secondary erythromelalgia (red, hot, painful extremities); very limited anecdotal evidence.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for erythromelalgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is highly investigational.
- ¿Qué evidencia existe?
- Tier C (highly investigational). Only isolated case reports; there are no randomized controlled trials. Erythromelalgia management depends on etiology: aspirin for myeloproliferative-neoplasm-associated forms (must rule out JAK2 V617F mutation), sodium channel blockers (mexiletine, lidocaine) for SCN9A and primary forms, gabapentinoids for neuropathic pain, cooling and avoidance of triggers. Aspirin use in MPN-associated forms is itself an exclusion for leech therapy, creating practical incompatibility.
- Riesgos principales
- Tissue breakdown or non-healing wounds in already fragile, hyperemic, painful skin
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening of the pain or erythema in the first 24 hours
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Permanent scars at bite sites
- Missing the diagnosis of a myeloproliferative neoplasm that requires hematology management
- Delay or replacement of evidence-based pharmacotherapy
- Quién no debería considerar esto
- Patients with MPN-associated erythromelalgia who should be on aspirin
- Patients on aspirin or antiplatelet therapy
- Patients with an active SCN9A pain crisis (sodium channel blocker first)
- Patients with concurrent skin breakdown in the affected area
- Patients with cooling-responsive symptoms who have not tried conventional medications
- Patients with severe anemia, hemophilia, or active infection
- Qué preguntar a su clínico
- Has my erythromelalgia been classified as primary (SCN9A or idiopathic) or secondary (MPN, autoimmune, drug-related)?
- Has a hematology workup been completed (CBC, JAK2 V617F, peripheral smear)?
- Have I tried aspirin (if MPN-associated), mexiletine, lidocaine patches, or gabapentinoids?
- What are my known triggers, and what is my cooling and trigger-avoidance plan?
- Has the practitioner explained why leech therapy is incompatible with aspirin in MPN-associated forms?
- What is the realistic expectation of benefit, and what is the duration?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Cuándo buscar atención urgente
- Sudden severe burning pain with skin breakdown, ulceration, or blackening (tissue breakdown — urgent care)
- New unilateral arm or leg swelling (DVT in MPN-associated forms)
- Sudden chest pain, shortness of breath, or stroke-like symptoms (thrombotic event)
- Spreading redness, pus, or red streaks (cellulitis or wound infection)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Qué NO significa esto
- This is not FDA-cleared for erythromelalgia.
- Isolated case reports do NOT establish efficacy versus aspirin (MPN-associated forms) or sodium-channel blockers.
- Mechanism rationale (anti-inflammation, microvascular) does NOT address SCN9A channelopathy or MPN thrombosis risk.
- Leech therapy is incompatible with aspirin, which is a key therapy in MPN-associated forms.
- Leech therapy is not a substitute for hematology workup or evidence-based pharmacotherapy.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- vascular
- ICD-10
- I73.81
- Safety tier
- high
Evidence Summary
Erythromelalgia is a rare disorder of episodic erythema, warmth, and burning pain in extremities, classified as primary (often SCN9A mutation) or secondary (myeloproliferative neoplasms, autoimmune disease). Conventional management includes cooling, aspirin (responsive in MPN-associated forms), sodium channel blockers (mexiletine, lidocaine), and gabapentinoids. No controlled clinical trial or case report of leech therapy for erythromelalgia has been published; use is investigational and mechanistic only. A practical incompatibility also exists: aspirin responsiveness in MPN-associated forms implicates platelet involvement, yet ongoing aspirin or antiplatelet use is an exclusion for leech therapy.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Wollina U (2010)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active deep vein thrombosis (acute phase <2 weeks)
- Critical limb ischemia (ABI <0.4)
- MPN-associated erythromelalgia requiring aspirin
- Active SCN9A pain crisis (consider sodium channel blocker first)
- Concurrent skin breakdown in affected area
- Cooling-responsive symptoms without medication trial
Related Conditions
Chronic Venous Insufficiency (CEAP C3-C5)
Off-label use with controlled trial evidence for symptomatic improvement in venous claudication, leg heaviness, and edema in CEAP C3-C5 stages.
Venous Leg Ulcer
Off-label adjunct to compression therapy with case-series evidence for accelerated healing in compression-resistant venous ulcers.
Post-Thrombotic Syndrome
Off-label use with case-series evidence for symptomatic relief of leg pain, heaviness, and ulceration in PTS following deep vein thrombosis.
Varicose Veins (Symptomatic Tributaries)
Investigational use for symptomatic relief of varicose tributary discomfort and inflammation; does not eliminate underlying venous reflux.